Effect of Obesity on Pharmacokinetics and Biologic Effect of Interferon-alpha in Hepatitis C
- 1 January 1997
- journal article
- Published by Springer Science and Business Media LLC in Digestive Diseases and Sciences
- Vol. 42 (1), 178-185
- https://doi.org/10.1023/a:1018865928308
Abstract
To examine potential adverse effects of obesityin reducing the response to interferon-alpha (IFN-alpha)in chronic hepatitis C (HCV), IFN-alpha and HCV RNAlevels in serum and the 2′,5′-oligoadenylatesynthetase (2-5 OAS) levels in peripheral bloodmononuclear cells (PBMC) were compared between six obeseand five nonobese patients before and after a single, 10mIU dose of IFN-alpha2b. There were nodifferences in the mean histologic activity index between thetwo groups. The maximal IFN concentration and the areaunder the serum IFN concentration-time curve were higherin nonobese patients. These two parameters were inversely correlated with body weight andbody surface area. No differences were found in the meanreduction in HCV RNA levels between the two groupsfollowing IFN-alpha. The maximal 2-5 OAS level after treatment divided by the pretreatment 2-5OAS level (2-5 OAS response ratio) was greater in thenonobese patients, suggesting stronger biologic responseupon exposure to exogenous IFN-alpha in nonobese patients.Keywords
This publication has 32 references indexed in Scilit:
- Significance of serum hepatitis C virus RNA levels in chronic hepatitis CThe Lancet, 1993
- Response related factors in recombinant interferon alfa-2b treatment of chronic hepatitis C.Gut, 1993
- Long-term follow-up of patients with chronic hepatitis C treated with α-interferonHepatology, 1992
- Phenobarbital Pharmacokinetics in ObesityClinical Pharmacokinetics, 1992
- Fat Body Mass and Pharmacokinetics of Oral 6-Mercaptopurine in Children with Acute Lymphoblastic LeukemiaTherapeutic Drug Monitoring, 1991
- Recombinant Interferon Alfa Therapy for Chronic Hepatitis CNew England Journal of Medicine, 1989
- Treatment of Chronic Hepatitis C with Recombinant Interferon AlfaNew England Journal of Medicine, 1989
- Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distributionCancer Chemotherapy and Pharmacology, 1989
- Relationship between in Vivo Insulin Resistance and Decreased Insulin Receptors in Obese Man*Journal of Clinical Endocrinology & Metabolism, 1979
- Correlation between insulin receptor binding in isolated fat cells and insulin sensitivity in obese human subjects.JCI Insight, 1976